Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.
about
A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels.Recent advances and clinical insights into the use of proteomics in the study of atherosclerosis.Apolipoprotein C-III Levels and Incident Coronary Artery Disease Risk: The EPIC-Norfolk Prospective Population Study.Diabetes and dyslipidemia: characterizing lipoprotein metabolism.Mass Spectrometric Studies of Apolipoprotein Proteoforms and Their Role in Lipid Metabolism and Type 2 Diabetes.Extracellular Matrix Proteomics Reveals Interplay of Aggrecan and Aggrecanases in Vascular Remodeling of Stented Coronary Arteries.Advances in quantifying apolipoproteins using LC-MS/MS technology: implications for the clinic.What are the prospects of apolipoprotein profiling for cardiovascular disease?ApoCIII as a Cardiovascular Risk Factor and Modulation by the Novel Lipid-Lowering Agent Volanesorsen.Core lipid, surface lipid and apolipoprotein composition analysis of lipoprotein particles as a function of particle size in one workflow integrating asymmetric flow field-flow fractionation and liquid chromatography-tandem mass spectrometry.Potential role of new molecular plasma signatures on cardiovascular risk stratification in asymptomatic individuals.Association of circulating metabolites with healthy diet and risk of cardiovascular disease: analysis of two cohort studies.LXR/RXR signaling and neutrophil phenotype following myocardial infarction classify sex differences in remodeling
P2860
Q38616263-098428E9-BC13-4599-8562-31DF740E1C7BQ39423557-806E157A-D4F5-4898-8D4A-1065C53AF6DEQ40214593-74AF5B26-9405-455D-A7DC-A1A90A5FAA0EQ41283425-24B729A7-5553-4E2F-8E5E-7D09B7541B15Q47163663-97106604-A975-41F0-A81F-28869FAF1BB9Q47655289-35F5E052-DBA5-4D92-924E-3AB9536C8192Q47859533-A387CD90-9588-450C-A526-4166ABF417D4Q48155948-957A5A95-59D0-48BB-8E26-0D94AB226663Q50075898-676261BB-0918-477B-A88C-F13612567548Q52326471-07BE7425-764F-44D2-8362-0F68E2EAEBFBQ52647946-EAA6919D-954B-4AD1-AFF0-73E7FDAB10D0Q55314521-EF9D1521-4E4D-4942-88C5-FC7B6B5B8B36Q58730141-A804AE84-CC05-4D22-B278-8C76319EFDB3
P2860
Very-Low-Density Lipoprotein-Associated Apolipoproteins Predict Cardiovascular Events and Are Lowered by Inhibition of APOC-III.
description
2017 nî lūn-bûn
@nan
2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2017 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
name
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@ast
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@en
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@nl
type
label
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@ast
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@en
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@nl
prefLabel
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@ast
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@en
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@nl
P2093
P2860
P50
P1476
Very-Low-Density Lipoprotein-A ...... red by Inhibition of APOC-III.
@en
P2093
Ferheen Baig
Friedrich Oberhollenzer
Georg Egger
Johann Willeit
Peter Santer
Peter Willeit
Raimund Pechlaner
Stefan Kiechl
Veronica J Alexander
Xiaoke Yin
P2860
P304
P356
10.1016/J.JACC.2016.11.065
P407
P577
2017-02-01T00:00:00Z